Medindia

X

Astex Pharma Announces It Will Halt Development of Lung Cancer Drug

by Kathy Jones on  September 22, 2012 at 8:36 PM Corporate News   - G J E 4
Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study.
 Astex Pharma Announces It Will Halt Development of Lung Cancer Drug
Astex Pharma Announces It Will Halt Development of Lung Cancer Drug
Advertisement

The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent.

Advertisement
The company said in a statement that no new safety issues were identified during the trial and that it would license the drug to any other companies interested in developing it further.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All